Literature DB >> 31821783

Adenosine Metabolism: Emerging Concepts for Cancer Therapy.

Detlev Boison1, Gennady G Yegutkin2.   

Abstract

Adenosine is a key metabolic and immune-checkpoint regulator implicated in the tumor escape from the host immune system. Major gaps in knowledge that impede the development of effective adenosine-based therapeutics include: (1) lack of consideration of redundant pathways controlling ATP and adenosine levels; (2) lack of distinction between receptor-dependent and -independent effects of adenosine, and (3) focus on extracellular adenosine without consideration of intracellular metabolism and compartmentalization. In light of current clinical trials, we provide an overview of adenosine metabolism and point out the need for a more careful evaluation of the entire purinome in emerging cancer therapies.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adenosine; adenosine kinase; adenosine receptors; biochemistry; cancer; epigenetics; immune checkpoint; intracellular; metabolism; therapy

Mesh:

Substances:

Year:  2019        PMID: 31821783      PMCID: PMC7224341          DOI: 10.1016/j.ccell.2019.10.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  91 in total

1.  Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.

Authors:  Tomasz Maj; Wei Wang; Joel Crespo; Hongjuan Zhang; Weimin Wang; Shuang Wei; Lili Zhao; Linda Vatan; Irene Shao; Wojciech Szeliga; Costas Lyssiotis; J Rebecca Liu; Ilona Kryczek; Weiping Zou
Journal:  Nat Immunol       Date:  2017-10-30       Impact factor: 25.606

Review 2.  Regulation of the T Cell Response by CD39.

Authors:  Maisa C Takenaka; Simon Robson; Francisco J Quintana
Journal:  Trends Immunol       Date:  2016-05-25       Impact factor: 16.687

Review 3.  The hypoxia-adenosine link during inflammation.

Authors:  Jessica L Bowser; Jae W Lee; Xiaoyi Yuan; Holger K Eltzschig
Journal:  J Appl Physiol (1985)       Date:  2017-08-10

Review 4.  Vesicular and conductive mechanisms of nucleotide release.

Authors:  Eduardo R Lazarowski
Journal:  Purinergic Signal       Date:  2012-04-12       Impact factor: 3.765

Review 5.  Targeting cancer-derived adenosine: new therapeutic approaches.

Authors:  Arabella Young; Deepak Mittal; John Stagg; Mark J Smyth
Journal:  Cancer Discov       Date:  2014-07-17       Impact factor: 39.397

6.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Authors:  Yannick Simoni; Etienne Becht; Michael Fehlings; Chiew Yee Loh; Si-Lin Koo; Karen Wei Weng Teng; Joe Poh Sheng Yeong; Rahul Nahar; Tong Zhang; Hassen Kared; Kaibo Duan; Nicholas Ang; Michael Poidinger; Yin Yeng Lee; Anis Larbi; Alexis J Khng; Emile Tan; Cherylin Fu; Ronnie Mathew; Melissa Teo; Wan Teck Lim; Chee Keong Toh; Boon-Hean Ong; Tina Koh; Axel M Hillmer; Angela Takano; Tony Kiat Hon Lim; Eng Huat Tan; Weiwei Zhai; Daniel S W Tan; Iain Beehuat Tan; Evan W Newell
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

Review 7.  Cancer metabolism: a therapeutic perspective.

Authors:  Ubaldo E Martinez-Outschoorn; Maria Peiris-Pagés; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Nat Rev Clin Oncol       Date:  2016-05-04       Impact factor: 66.675

Review 8.  Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade.

Authors:  Gennady G Yegutkin
Journal:  Biochim Biophys Acta       Date:  2008-02-12

9.  The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment.

Authors:  Elena De Marchi; Elisa Orioli; Anna Pegoraro; Sabina Sangaletti; Paola Portararo; Antonio Curti; Mario Paolo Colombo; Francesco Di Virgilio; Elena Adinolfi
Journal:  Oncogene       Date:  2019-01-17       Impact factor: 9.867

10.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Authors:  Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; John P Ray; Carl G de Boer; Russell W Jenkins; David J Lieb; Jonathan H Chen; Dennie T Frederick; Michal Barzily-Rokni; Samuel S Freeman; Alexandre Reuben; Paul J Hoover; Alexandra-Chloé Villani; Elena Ivanova; Andrew Portell; Patrick H Lizotte; Amir R Aref; Jean-Pierre Eliane; Marc R Hammond; Hans Vitzthum; Shauna M Blackmon; Bo Li; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; Zachary A Cooper; Cloud P Paweletz; David A Barbie; Anat Stemmer-Rachamimov; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Nir Hacohen
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

View more
  68 in total

Review 1.  Regulation of tumor infiltrated innate immune cells by adenosine.

Authors:  Regina Strakhova; Octavia Cadassou; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Purinergic Signal       Date:  2020-06-12       Impact factor: 3.765

2.  Comparison of peripheral blood mononuclear cell isolation techniques and the impact of cryopreservation on human lymphocytes expressing CD39 and CD73.

Authors:  Ross J Turner; Nicholas J Geraghty; Jonathan G Williams; Diane Ly; Daniel Brungs; Martin G Carolan; Thomas V Guy; Debbie Watson; Jeremiah F de Leon; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2020-08-05       Impact factor: 3.765

Review 3.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

Review 4.  The adenosine pathway in immuno-oncology.

Authors:  Bertrand Allard; David Allard; Laurence Buisseret; John Stagg
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

5.  PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.

Authors:  Kaikai Yi; Qi Zhan; Qixue Wang; Yanli Tan; Chuan Fang; Yunfei Wang; Junhu Zhou; Chao Yang; Yansheng Li; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

Review 6.  Adenosine kinase: A key regulator of purinergic physiology.

Authors:  Detlev Boison; Michael F Jarvis
Journal:  Biochem Pharmacol       Date:  2020-11-06       Impact factor: 5.858

7.  Adenosine Kinase Expression Determines DNA Methylation in Cancer Cell Lines.

Authors:  Amir E Wahba; Denise Fedele; Hoda Gebril; Enmar AlHarfoush; Kiran S Toti; Kenneth A Jacobson; Detlev Boison
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-16

Review 8.  Neutrophils: fast and furious-the nucleotide pathway.

Authors:  Dominique S Rubenich; Priscila O de Souza; Natalia Omizzollo; Gabriela S Lenz; Jean Sevigny; Elizandra Braganhol
Journal:  Purinergic Signal       Date:  2021-04-29       Impact factor: 3.765

Review 9.  Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy.

Authors:  Wen-Jun Zhang
Journal:  Purinergic Signal       Date:  2021-01-09       Impact factor: 3.765

10.  The purinergic receptor P2Y11 choreographs the polarization, mitochondrial metabolism, and migration of T lymphocytes.

Authors:  Carola Ledderose; Sophie Bromberger; Christian J Slubowski; Koichiro Sueyoshi; Dilan Aytan; Yong Shen; Wolfgang G Junger
Journal:  Sci Signal       Date:  2020-09-29       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.